The formation of a four-chambered heart with ventricular chambers aligned in a left-right orientation begins with the rightward looping of the linear heart tube in accordance with the left-right embryonic axis. The functional specification of the ventricular chambers in the looped heart occurs with the formation of a trabeculated myocardium along the outer curvature of the realigned heart tube. Two major signal transduction pathways are involved in this process, the retinoic acid and neuregulin signaling pathways, with the retinoic acid pathway also participating in rightward heart tube looping. With the establishment of the atrial and ventricular chambers, maintenance of a unidirectional flow of blood between the two chambers must be ensured. To achieve this, heart valves develop at the atrioventricular juncture. This process begins with formation of endocardial cushions, the primordia of heart valves, and ends with formation of heart valve leaflets. Underlying this process is a complex network of signal transduction pathways that mediate communication between the endocardial and myocardial cell layers to form the endocardial cushions and nascent heart valve. Some of the signaling molecules involved are vascular endothelial growth factor, Wnts, bone morphogenetic proteins, epidermal growth factor, hyaluronic acid, neurofibromin, and calcium.
Get full access to this article
View all access options for this article.
References
1.
Wagner M, Siddiqui MAQ. Signal transduction in early heart development (I): cardiogenic induction and heart tube formation. Exp Biol Med232:852–865, 2007.
2.
Brand T. Heart development: molecular insights into cardiac specification and early morphogenesis. Dev Biol258:1–19, 2003.
3.
Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA. Right ventricular myocardium derives from the anterior heart field. Circ Res95:261–268, 2004.
4.
Iwamoto R, Mekada E. ErbB and HB-EGF signaling in heart development and function. Cell Struct Funct31:1–14, 2006.
5.
Fishman MC, Olson EN. Parsing the heart: genetic modules for organ assembly. Cell91:153–156, 1997.
6.
Christoffels VM, Habets PE, Franco D, Campione M, de Jong F, Lamers WH, Bao ZZ, Palmer S, Biben C, Harvey RP, Moorman AF. Chamber formation and morphogenesis in the developing mammalian heart. Dev Biol223:266–278, 2000.
7.
Srivastava D, Olson EN. A genetic blueprint for cardiac development. Nature407:221–226, 2000.
8.
Christoffels VM, Burch JB, Moorman AF. Architectural plan for the heart: early patterning and delineation of the chambers and the nodes. Trends Cardiovasc Med14:301–307, 2004.
9.
Harvey RP. Patterning the vertebrate heart. Nat Rev Genet3:544–556, 2002.
10.
Icardo JM, Fernandez-Teran A. Morphologic study of ventricular trabeculation in the embryonic chick heart. Acta Anat (Basel)130: 264–274, 1987.
11.
Sedmera D, Pexieder T, Vuillemin M, Thompson RP, Anderson RH. Developmental patterning of the myocardium. Anat Rec258:319–337, 2000.
12.
Kastner P, Grondona JM, Mark M, Gansmuller A, LeMeur M, Decimo D, Vonesch JL, Dolle P, Chambon P. Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell78:987–1003, 1994.
13.
Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR, Evans RM. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev8:1007–1018, 1994.
14.
Gruber PJ, Kubalak SW, Pexieder T, Sucov HM, Evans RM, Chien KR. RXR alpha deficiency confers genetic susceptibility for aortic sac, conotruncal, atrioventricular cushion, and ventricular muscle defects in mice. J Clin Invest98:1332–1343, 1996.
15.
Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature378:386–390, 1995.
16.
Kramer R, Bucay N, Kane DJ, Martin LE, Tarpley JE, Theill LE. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. Proc Natl Acad Sci U S A93:4833–4838, 1996.
17.
Liu X, Hwang H, Cao L, Buckland M, Cunningham A, Chen J, Chien KR, Graham RM, Zhou M. Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci U S A95:13024–13029, 1998.
18.
Chen H, Shi S, Acosta L, Li W, Lu J, Bao S, Chen Z, Yang Z, Schneider MD, Chien KR, Conway SJ, Yoder MC, Haneline LS, Franco D, Shou W. BMP-10 is essential for maintaining cardiac growth during murine cardiogenesis. Development131:2219–2231, 2004.
19.
Chen H, Yong W, Ren S, Shen W, He Y, Cox KA, Zhu W, Li W, Soonpaa M, Payne RM, Franco D, Field LJ, Rosen V, Wang Y, Shou W. Overexpression of bone morphogenetic protein 10 in myocardium disrupts cardiac postnatal hypertrophic growth. J Biol Chem281: 27481–27491, 2006.
20.
Nebigil CG, Maroteaux L. A novel role for serotonin in heart. Trends Cardiovasc Med11:329–335, 2001.
21.
Ross AC. Cellular metabolism and activation of retinoids: roles of cellular retinoid-binding proteins. FASEB J7:317–327, 1993.
22.
Godsave SF, Koster CH, Getahun A, Mathu M, Hooiveld M, van der Wees J, Hendriks J, Durston AJ. Graded retinoid responses in the developing hindbrain. Dev Dyn213:39–49, 1998.
23.
Dupe V, Lumsden A. Hindbrain patterning involves graded responses to retinoic acid signalling. Development128:2199–2208, 2001.
24.
Kalter H, Warkany J. Experimental production of congenital maiformations in mammals by metabolic procedure. Physiol Rev39:69–115, 1959.
25.
Niederreither K, Vermot J, Messaddeq N, Schuhbaur B, Chambon P, Dolle P. Embryonic retinoic acid synthesis is essential for heart morphogenesis in the mouse. Development128:1019–1031, 2001.
26.
Yutzey KE, Rhee JT, Bader D. Expression of the atrial-specific myosin heavy chain AMHC1 and the establishment of anteroposterior polarity in the developing chicken heart. Development120:871–883, 1994.
27.
Chazaud C, Chambon P, Dolle P. Retinoic acid is required in the mouse embryo for left-right asymmetry determination and heart morphogenesis. Development126:2589–2596, 1999.
28.
Zile MH, Kostetskii I, Yuan S, Kostetskaia E, St Amand TR, Chen Y, Jiang W. Retinoid signaling is required to complete the vertebrate cardiac left/right asymmetry pathway. Dev Biol223:323–338, 2000.
29.
Dickman ED, Smith SM. Selective regulation of cardiomyocyte gene expression and cardiac morphogenesis by retinoic acid. Dev Dyn206: 39–48, 1996.
30.
Keegan BR, Feldman JL, Begemann G, Ingham PW, Yelon D. Retinoic acid signaling restricts the cardiac progenitor pool. Science307:247–249, 2005.
31.
Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol46:451–480, 2006.
32.
Evans RM. The molecular basis of signaling by vitamin A and its metabolites. Harvey Lect90:105–117, 1994.
33.
Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J10:940–954, 1996.
34.
Leid M, Kastner P, Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem Sci17:427–433, 1992.
35.
Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell83:841–850, 1995.
36.
Kastner P, Mark M, Ghyselinck N, Krezel W, Dupe V, Grondona JM, Chambon P. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR/RAR functional units during mouse development. Development124:313–326, 1997.
37.
Heyman RA, Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, Thaller C. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell68:397–406, 1992.
38.
Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P, Levin AA. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A90:30–34, 1993.
39.
Conlon RA. Retinoic acid and pattern formation in vertebrates. Trends Genet11:314–319, 1995.
40.
Napoli JL. Retinoic acid biosynthesis and metabolism. FASEB J10: 993–1001, 1996.
41.
Maden M. The role of retinoic acid in embryonic and post-embryonic development. Proc Nutr Soc59:65–73, 2000.
42.
Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem J348(Pt 3):481–495, 2000.
43.
Reijntjes S, Blentic A, Gale E, Maden M. The control of morphogen signalling: regulation of the synthesis and catabolism of retinoic acid in the developing embryo. Dev Biol285:224–237, 2005.
Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature378:390–394, 1995.
46.
Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature378:394–398, 1995.
47.
Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys58:903–913, 2004.
48.
Wheatley SC, Isacke CM, Crossley PH. Restricted expression of the hyaluronan receptor, CD44, during postimplantation mouse embryogenesis suggests key roles in tissue formation and patterning. Development119:295–306, 1993.
49.
Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, Calabro A Jr., Kubalak S, Klewer SE, McDonald JA. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J Clin Invest106:349–360, 2000.
50.
Garratt AN. “To erb-B or not to erb-B …” Neuregulin-1/ErbB signaling in heart development and function. J Mol Cell Cardiol41: 215–218, 2006.
51.
Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol41:228–235, 2006.
52.
Garratt AN, Ozcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med13:80–86, 2003.
53.
Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell80:213–223, 1995.
54.
Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem273:11987–11990, 1998.
55.
Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell103: 211–225, 2000.
56.
Lamers WH, Moorman AF. Cardiac septation: a late contribution of the embryonic primary myocardium to heart morphogenesis. Circ Res91:93–103, 2002.
Rivera-Feliciano J, Lee KH, Kong SW, Rajagopal S, Ma Q, Springer Z, Izumo S, Tabin CJ, Pu WT. Development of heart valves requires Gata4 expression in endothelial-derived cells. Development133: 3607–3618, 2006.
59.
Chan-Thomas PS, Thompson RP, Robert B, Yacoub MH, Barton PJ. Expression of homeobox genes Msx-1 (Hox-7) and Msx-2 (Hox-8) during cardiac development in the chick. Dev Dyn197:203–216, 1993.
60.
Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, Epstein JA, de Crombrugghe B. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A101:6502–6507, 2004.
61.
Rivera-Feliciano J, Tabin CJ. Bmp2 instructs cardiac progenitors to form the heart-valve-inducing field. Dev Biol295:580–588, 2006.
62.
Ramsdell AF, Moreno-Rodriguez RA, Wienecke MM, Sugi Y, Turner DK, Mjaatvedt CH, Markwald RR. Identification of an autocrine signaling pathway that amplifies induction of endocardial cushion tissue in the avian heart. Acta Anat (Basel)162:1–15, 1998.
63.
Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol39:1890–1900, 2002.
64.
Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res49:568–581, 2001.
65.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med9:669–776, 2003.
66.
Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond)109:227–241, 2005.
67.
Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med6:389–395, 2000.
68.
Miquerol L, Gertsenstein M, Harpal K, Rossant J, Nagy A. Multiple developmental roles of VEGF suggested by a LacZ-tagged allele. Dev Biol212:307–322, 1999.
69.
Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P, Keshet E. A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects. Development128:1531–1538, 2001.
70.
Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res95:459–470, 2004.
71.
Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans31:1171–1177, 2003.
72.
Armesilla AL, Lorenzo E, Gomez del Arco P, Martinez-Martinez S, Alfranca A, Redondo JM. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol Cell Biol19:2032–2043, 1999.
73.
Johnson EN, Lee YM, Sander TL, Rabkin E, Schoen FJ, Kaushal S, Bischoff J. NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells. J Biol Chem278:1686–1692, 2003.
74.
Abedi H, Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J Biol Chem272:15442–15451, 1997.
75.
Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascuar endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene15:2169–2177, 1997.
76.
Goligorsky MS, Abedi H, Noiri E, Takhtajan A, Lense S, Romanov V, Zachary I. Nitric oxide modulation of focal adhesions in endothelial cells. Am J Physiol276:C1271–C1281, 1999.
77.
Grego-Bessa J, Diez J, Timmerman L, de la Pompa JL. Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. Cell Cycle3:718–721, 2004.
78.
Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC, de la Pompa JL. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev18:99–115, 2004.
79.
Romano LA, Runyan RB. Slug is an essential target of TGFbeta2 signaling in the developing chicken heart. Dev Biol223:91–102, 2000.
80.
Takase M, Imamura T, Sampath TK, Takeda K, Ichijo H, Miyazono K, Kawabata M. Induction of Smad6 mRNA by bone morphogenetic proteins. Biochem Biophys Res Commun244:26–29, 1998.
81.
Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MA Jr., Falb D, Huszar D. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet24:171–174, 2000.
82.
Weinmaster G. The ins and outs of notch signaling. Mol Cell Neurosci9:91–102, 1997.
83.
Fleming RJ. Structural conservation of Notch receptors and ligands. Semin Cell Dev Biol9:599–607, 1998.
84.
Schweisguth F. Notch signaling activity. Curr Biol14:R129–R138, 2004.
85.
Fitzgerald K, Greenwald I. Interchangeability of Caenorhabditis elegans DSL proteins and intrinsic signalling activity of their extracellular domains in vivo. Development121:4275–4282, 1995.
86.
Dickson MC, Slager HG, Duffie E, Mummery CL, Akhurst RJ. RNA and protein localisations of TGF beta 2 in the early mouse embryo suggest an involvement in cardiac development. Development117: 625–639, 1993.
87.
Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol2: 84–89, 2000.
88.
Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol2:76–83, 2000.
89.
Romano LA, Runyan RB. Slug is a mediator of epithelial-mesenchymal cell transformation in the developing chicken heart. Dev Biol212:243–254, 1999.
90.
Carmona R, Gonzalez-Iriarte M, Macias D, Perez-Pomares JM, Garcia-Garrido L, Munoz-Chapuli R. Immunolocalization of the transcription factor Slug in the developing avian heart. Anat Embryol (Berl)201:103–109, 2000.
91.
Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays23: 912–923, 2001.
92.
De Craene B, van Roy F, Berx G. Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal17:535–547, 2005.
93.
Raya A, Kawakami Y, Rodriguez-Esteban C, Buscher D, Koth CM, Itoh T, Morita M, Raya RM, Dubova I, Bessa JG, de la Pompa JL, Belmonte JC. Notch activity induces Nodal expression and mediates the establishment of left-right asymmetry in vertebrate embryos. Genes Dev17:1213–1218, 2003.
94.
Krebs LT, Iwai N, Nonaka S, Welsh IC, Lan Y, Jiang R, Saijoh Y, O’Brien TP, Hamada H, Gridley T. Notch signaling regulates left-right asymmetry determination by inducing Nodal expression. Genes Dev17:1207–1212, 2003.
95.
Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, Qi M, Trask BJ, Kuo WL, Cochran J, Costa T, Pierpont ME, Rand EB, Piccoli DA, Hood L, Spinner NB. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet16:243–251, 1997.
96.
Lu F, Morrissette JJ, Spinner NB. Conditional JAG1 mutation shows the developing heart is more sensitive than developing liver to JAG1 dosage. Am J Hum Genet72:1065–1070, 2003.
97.
McElhinney DB, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, Goldmuntz E. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation106:2567–2574, 2002.
98.
Lorent K, Yeo SY, Oda T, Chandrasekharappa S, Chitnis A, Matthews RP, Pack M. Inhibition of Jagged-mediated Notch signaling disrupts zebrafish biliary development and generates multi-organ defects compatible with an Alagille syndrome phenocopy. Development131:5753–5766, 2004.
99.
Zhong TP, Childs S, Leu JP, Fishman MC. Gridlock signalling pathway fashions the first embryonic artery. Nature414:216–220, 2001.
100.
Weinstein BM, Stemple DL, Driever W, Fishman MC. Gridlock, a localized heritable vascular patterning defect in the zebrafish. Nat Med1:1143–1147, 1995.
101.
Towbin JA, McQuinn TC. Gridlock: a model for coarctation of the aorta? Nat Med1:1141–1142, 1995.
102.
Zhong TP, Rosenberg M, Mohideen MA, Weinstein B, Fishman MC. Gridlock, an HLH gene required for assembly of the aorta in zebrafish. Science287:1820–1824, 2000.
103.
Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL, Gridley T. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev14:1343–1352, 2000.
104.
Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M. The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev18:901–911, 2004.
105.
Rutenberg JB, Fischer A, Jia H, Gessler M, Zhong TP, Mercola M. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. Development133: 4381–4390, 2006.
106.
Baron M. An overview of the Notch signalling pathway. Semin Cell Dev Biol14:113–119, 2003.
107.
Hurlstone AF, Haramis AP, Wienholds E, Begthel H, Korving J, Van Eeden F, Cuppen E, Zivkovic D, Plasterk RH, Clevers H. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature425:633–637, 2003.
108.
Gitler AD, Lu MM, Jiang YQ, Epstein JA, Gruber PJ. Molecular markers of cardiac endocardial cushion development. Dev Dyn228: 643–650, 2003.
109.
Keyes WM, Logan C, Parker E, Sanders EJ. Expression and function of bone morphogenetic proteins in the development of the embryonic endocardial cushions. Anat Embryol (Berl)207:135–147, 2003.
110.
Lyons KM, Pelton RW, Hogan BL. Patterns of expression of murine Vgr-1 and BMP-2a RNA suggest that transforming growth factor-beta-like genes coordinately regulate aspects of embryonic development. Genes Dev3:1657–1668, 1989.
111.
Lyons KM, Pelton RW, Hogan BL. Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-2A (BMP-2A). Development109:833–844, 1990.
112.
Somi S, Buffing AA, Moorman AF, Van Den Hoff MJ. Dynamic patterns of expression of BMP isoforms 2, 4, 5, 6, and 7 during chicken heart development. Anat Rec A Discov Mol Cell Evol Biol279:636–651, 2004.
113.
Bernanke DH, Markwald RR. Migratory behavior of cardiac cushion tissue cells in a collagen-lattice culture system. Dev Biol91:235–245, 1982.
114.
Sugi Y, Yamamura H, Okagawa H, Markwald RR. Bone morphogenetic protein-2 can mediate myocardial regulation of atrioventricular cushion mesenchymal cell formation in mice. Dev Biol269:505–518, 2004.
115.
Gaussin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, Behringer RR, Schneider MD. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc Natl Acad Sci U S A99:2878–2883, 2002.
116.
Yamagishi T, Nakajima Y, Miyazono K, Nakamura H. Bone morphogenetic protein-2 acts synergistically with transforming growth factor-beta3 during endothelial-mesenchymal transformation in the developing chick heart. J Cell Physiol180:35–45, 1999.
117.
Nakajima Y, Yamagishi T, Hokari S, Nakamura H. Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec258:119–127, 2000.
118.
Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, Lee DC. Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J22:2704–2716, 2003.
119.
Chen B, Bronson RT, Klaman LD, Hampton TG, Wang JF, Green PJ, Magnuson T, Douglas PS, Morgan JP, Neel BG. Mice mutant for Egfr and Shp2 have defective cardiac semilunar valvulogenesis. Nat Genet24:296–299, 2000.
120.
Schroeder JA, Jackson LF, Lee DC, Camenisch TD. Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J Mol Med81:392–403, 2003.
121.
Xu GF, O’Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, Weiss R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell62:599–608, 1990.
122.
Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell63:851–859, 1990.
123.
Gitler AD, Epstein JA. Regulating heart development: the role of Nf1. Cell Cycle2:96–98, 2003.
124.
Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev8:1019–1029, 1994.
125.
Gitler AD, Zhu Y, Ismat FA, Lu MM, Yamauchi Y, Parada LF, Epstein JA. Nf1 has an essential role in endothelial cells. Nat Genet33:75–79, 2003.
126.
Lakkis MM, Epstein JA. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development125:4359–4367, 1998.
127.
Ichida M, Finkel T. Ras regulates NFAT3 activity in cardiac myocytes. J Biol Chem276:3524–3530, 2001.
128.
Yutzey KE, Colbert M, Robbins J. Ras-related signaling pathways in valve development: ebb and flow. Physiology (Bethesda)20:390–397, 2005.
129.
Gelb BD, Tartaglia M. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet15(Spec No 2):R220–R226, 2006.
130.
Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet6:45–68, 2005.
131.
Ishizawa A, Oho S, Dodo H, Katori T, Homma SI. Cardiovascular abnormalities in Noonan syndrome: the clinical findings and treatments. Acta Paediatr Jpn38:84–90, 1996.
132.
Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet39:70–74, 2007.
133.
Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet39:75–79, 2007.
134.
Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonan syndrome. Nat Genet38:331–336, 2006.
135.
Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet29:465–468, 2001.
136.
Krenz M, Yutzey KE, Robbins J. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling. Circ Res97: 813–820, 2005.
137.
Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, Neel BG. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med10:849–857, 2004.
138.
Uhlen P, Burch PM, Zito CI, Estrada M, Ehrlich BE, Bennett AM. Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proc Natl Acad Sci U S A103:2160–2165, 2006.
139.
Chang CP, Neilson JR, Bayle JH, Gestwicki JE, Kuo A, Stankunas K, Graef IA, Crabtree GR. A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell118:649–663, 2004.
140.
Im SH, Rao A. Activation and deactivation of gene expression by Ca2+/calcineurin-NFAT-mediated signaling. Mol Cells18:1–9, 2004.
141.
Lambrechts D, Carmeliet P. Sculpting heart valves with NFATc and VEGF. Cell118:532–534, 2004.
142.
de la Pompa JL, Timmerman LA, Takimoto H, Yoshida H, Elia AJ, Samper E, Potter J, Wakeham A, Marengere L, Langille BL, Crabtree GR, Mak TW. Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature392:182–186, 1998.
143.
Cusick ME, Klitgord N, Vidal M, Hill DE. Interactome: gateway into systems biology. Hum Mol Genet14(Spec No. 2):R171–R181, 2005.
